Ignite Creation Date:
2025-12-25 @ 1:40 AM
Ignite Modification Date:
2025-12-31 @ 10:58 AM
Study NCT ID:
NCT02864394
Status:
COMPLETED
Last Update Posted:
2024-09-19
First Post:
2016-08-10
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-09-07
Start Date Type:
ACTUAL
Primary Completion Date:
2019-09-09
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-10-14
Completion Date Type:
ACTUAL
First Submit Date:
2016-08-10
First Submit QC Date:
None
Study First Post Date:
2016-08-12
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2020-09-08
Results First Submit QC Date:
None
Results First Post Date:
2020-10-05
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-08-30
Last Update Post Date:
2024-09-19
Last Update Post Date Type:
ACTUAL